| Date | Acquired company | Acquiring company | Amount | Related |
|---|---|---|---|---|
| 2016-01-11 | IOmet (UK) | Merck&Co (USA - NJ) | up to $ 400 million | Cancer - Oncology |
| 2016-01-11 | AbVitro (USA - MA) | Juno Therapeutics (USA - WA) | cell therapy cancer - oncology |
|
| 2016-01-11 | Tensha Therapeutics (USA - MA) | Roche (Switzerland) | up to $535 million | |
| 2016-01-08 | bacteriophage assets from Novolytics (UK) | Ampliphi Biosciences (USA - VA) | undisclosed | |
| 2016-01-07 | Anterios (USA - NY) | Allergan (Ireland) | upfront payment of $90 million and potential development and commercialization milestone payments | Dermatological diseases Aesthetic medicine |
| 2015-12-23 | Crucell Sweden AB (Sweden) | Valneva (France - Austria) | € 45 million | Infectious diseases |
| 2015-12-22 | Synabs (Belgium) | Biotech Investissement (France) | production manufacturing monoclonal antibody |
|
| 2015-12-21 | Catherex (USA - MA) | Amgen (USA - CA) | $ 10.5 million and milestone payments | Cancer - Oncology |
| 2015-12-21 | ALK\'s European veterinary business (Denmark) | Fidelio Capital (Sweden) | undisclosed | Veterinary medicine |
| 2015-12-17 | Open Monoclonal Technology (OMT) (USA - CA) | Ligand Pharmaceuticals (USA - CA) | $178 million | Technology - Services |
| 2015-12-16 | Takeda’s respiratory business (Japan) | AstraZeneca (UK) | $575 million | Respiratory diseases |
| 2015-12-10 | Fluofarma (France) | Porsolt (France) | undisclosed | CRO Technology - Services |
| 2015-12-08 | Cardioxyl Pharmaceutical (USA - NC) | BMS (USA - NY) | up to 2.075 billion | Cardiovascular diseases |
| 2015-11-25 | Biopta (UK) | Reprocell (Japan) | undisclosed | Technology - Services |
| 2015-11-20 | female health care businesses from Famy Care (India), now known as Jai Pharma | Mylan (USA - PA) | up to $ 800 million | Women health |
| 2015-11-13 | Perrigo (Ireland) | Mylan (USA - PA) | $ 28.9 billion | Generics OTC |
| 2015-11-11 | Axiomx (USA - CT) | Abcam (UK) | up to $ 45 million | Technology - Services |
| 2015-11-06 | ZS Pharma (USA - CA) | AstraZeneca (UK) | $2.7 billion | Cardiovascular diseases Metabolic diseases |
| 2015-11-04 | Novira Therapeutics (USA - PA) | Johnson&Johnson (J&J) (USA - NJ) | undisclosed | Infectious diseases |
| 2015-11-02 | Seahorse Bioscience (USA - MA) | Agilent Technologies (USA - CA) | $235 million | Technology - Services |
